Johnson & Johnson said on Tuesday it would restart its COVID-19 Janssen vaccine shipments to Europe, after the European Medicines Agency demanded that a “warning about unusual blood clots with low blood platelets” be included in the pharmaceutical’s product information for the shots.
The outlook: The EU, for now, is more focused on accelerating its struggling vaccination campaigns, which are only beginning to catch up after three months of bureaucratic and logistical delays. Only 7% of the European population has been fully vaccinated, compared with 26% in the U.S. and 15% in the U.K.